Boston Scientific Corp., the Natick-based medical device company, has completed the purchase of Minnesota’s Atritech Inc. for $100 million.
The deal also includes contingency payments of up to $275 million based on regulatory and revenue criteria through 2015.
Atritech makes a device designed to prevent clots by closing a patient’s left atrial appendage. Boston Scientific said the product offers a new way to treat atrial fibrillation patients with high stroke risk.
BSX announced in January that it had signed a definitive merger agreement with Atritech.
